Yesim Eralp

home / authors / yesim-eralp

Articles

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

Nagi El Saghir;Yoon Sim Yap;Yesim Eralp;Seock-Ah Im;Hamdy Abdel Azim;Julie Rihani;Nikita Volkov;Shin-Cheh Chen;Hakan Harputluoglu;Patrapim Sunpaweravong;Yuan-Ching Chang;Teresa Delgar Alfaro;Jiwen Wu;Huilin Hu;Melissa Gao;Yen-Shen Lu
August 15th 2024
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

Melissa Gao;Yen-Shen Lu;Eznal Izwadi Bin Mohd Mahidin;Hamdy Abdel Azim;Yesim Eralp;Yoon Sim Yap;Seock-Ah Im;Julie Rihani;James Bowles;Teresa Delgar Alfaro;Jiwen Wu;Khemaies Slimane;Nagi El Saghir
April 28th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Published: May 27th 2011 | Updated: November 21st 2024
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: November 21st 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
Published: April 21st 2021 | Updated: November 21st 2024
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma